New Migraine Treatment
Migraines are one of the most common and debilitating conditions in the United States. Migraines are a condition characterized by recurrent attacks of moderate to severe headaches, most commonly on one side of the head. Some people with migraines may also experience visual disturbances, such as blind spots, tunnel vision, or temporary blindness. During a migraine, people are often very sensitive to light, sound and may become nauseated or vomit.
According to the Migraine Research Foundation, migraine is an extraordinarily prevalent condition, with estimates that nearly 1 in every 4 households include someone suffering from migraines.? This equates to approximately 39 million men and women in the U.S. experience migraines. Of these, around 4 million have at least 15 migraine days every month. Migraines are three times more common in women than in men.
There are several medications and non-drug therapies that can help to prevent migraine attacks, or at least lessen their severity. However, some migraine patients fail to respond to existing treatments, highlighting the need for more therapeutic options.
Presented at Anesthesiology 2017 (the annual meeting of the American Society of Anesthesiologists), a recent study of migraine patients treated with intravenous ketamine infusions found that greater than 75% of migraine patients reported improvements in their pain intensity at the end of their treatment period.